Co-Spray Dried Nafamostat Mesylate with Lecithin and Mannitol as Respirable Microparticles for Targeted Pulmonary Delivery: Pharmacokinetics and Lung Distribution in Rats

• Published in: Pharmaceutics Vol. 13; no. 9; p. 1519
• Main Authors: Kang, Ji-Hyun, Kim, Young-Jin, Yang, Min-Seok, Shin, Dae Hwan, Kim, Dong-Wook, Park, Il Yeong, Park, Chun-Woong
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 19-09-2021; MDPI
• Subjects: Anticoagulants; Bioavailability; co-spray; Coronaviruses; COVID-19; Decomposition; Disease transmission; Drug dosages; dry powder inhaler; Efficiency; Infections; Laboratories; lecithin; mannitol; Morphology; nafamostat mesylate; Particle size; Pharmaceutical industry; Pharmacokinetics; Proteins; Severe acute respiratory syndrome coronavirus 2; Spectrum analysis; Viral infections; Viruses; United States > US; Japan; Germany; COVID-19; lecithin; dry powder inhaler; mannitol; nafamostat mesylate; co-spray
• DOI: 10.3390/pharmaceutics13091519
• EISSN: 1999-4923

Coronavirus disease 2019 (COVID-19), caused by a new strain of coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly worldwide. Nafamostat mesylate (NFM) suppresses transmembrane serine protease 2 and SARS-CoV-2 S protein-mediated fusion. In this study, pharmacokinetics and lung distribution of NFM, administered via intravenous and intratracheal routes, were determined using high performance liquid chromatography analysis of blood plasma, lung lumen using bronchoalveolar lavage fluid, and lung tissue. Intratracheal administration had higher drug delivery and longer residual time in the lung lumen and tissue, which are the main sites of action, than intravenous administration. We confirmed the effect of lecithin as a stabilizer through an ex vivo stability test. Lecithin acts as an inhibitor of carboxylesterase and delays NFM decomposition. We prepared inhalable microparticles with NFM, lecithin, and mannitol via the co-spray method. The formulation prepared using an NFM:lecithin:mannitol ratio of 1:1:100 had a small particle size and excellent aerodynamic performance. Spray dried microparticles containing NFM, lecithin, and mannitol (1:1:100) had the longest residual time in the lung tissue. In conclusion, NFM-inhalable microparticles were prepared and confirmed to be delivered into the respiratory tract, such as lung lumen and lung tissue, through in vitro and in vivo evaluations.